This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging,
parallel-group study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics
of S-888711 in the treatment of subjects with immune thrombocytopenia. Eligible subjects will
be randomized into one of four treatment groups to receive S-888711 0.5 mg, 0.75 mg, or 1.0
mg or placebo.